Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

Background: Phase 3 studies of immune checkpoint inhibitors have not shown a survival benefit in prostate cancer, but some patients have a profound anticancer response. Patients and Methods: We evaluated the efficacy of the CTLA-4 targeted agent, ipilimumab, in metastatic prostate cancer patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Graff, Julie N., Stein, Mark N., Surana, Rishi, Al Rabadi, Luai, Liu, Eric, Fong, Lawrence, Bailey, Shawna, Latour, Emile, Newby, Timothy A., Moran, Amy E., Beer, Tomasz M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426513/
https://www.ncbi.nlm.nih.gov/pubmed/32850444
http://dx.doi.org/10.3389/fonc.2020.01381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426513/
https://www.ncbi.nlm.nih.gov/pubmed/32850444
http://dx.doi.org/10.3389/fonc.2020.01381

Ejemplares similares